Autolus Therapeutics Stock
Autolus Therapeutics plc
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Christian Martin Itin
- Employees
- 752
- Market cap
- $426 M
- IPO
- 22/06/2018
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is…
Autolus Therapeutics stock: price history
1D
-7.0%
1W
-11.6%
1M
-14.4%
6M
+0.0%
YTD
-19.6%
1Y
-4.8%
2Y
-64.5%
5Y
-73.9%
10Y
–
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~24% stronger price swings than usual
Ask the agents about Autolus Therapeutics
Analyst assessment of Autolus Therapeutics
PRICE TARGET LOW
US$7.60
CONSENSUS
US$8.87
MEDIAN
US$8.00
PRICE TARGET HIGH
US$11.00
0
STRONG BUY
11
BUY
3
HOLD
0
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 03/08/2026
Autolus Therapeutics stock metrics
P/E
-1.51
P/B
5.69
EV/EBITDA
-1.53
RETURN ON EQUITY
-52.3%
NET MARGIN
-85.6%
DEBT/EQUITY
1.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
90.4%
FLOAT SHARES
240,530,821
AVG. DAILY VOLUME (30D)
1,668,772
Insider transactions (SEC)
Piccina Cintia
Piccina Cintia
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -7.0%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Autolus Therapeutics stock
What does Autolus Therapeutics do?
Autolus Therapeutics plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Christian Martin Itin, the company employs around 752 people.
The IPO was on 22/06/2018; the stock trades on NASDAQ under the ticker AUTL.
What do analysts say about Autolus Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 03/08/2026).
The average price target is US$8.87, ranging from US$7.60 to US$11.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Autolus Therapeutics report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 24% stronger than usual.
Does Autolus Therapeutics pay a dividend?
No, Autolus Therapeutics currently does not pay a dividend.
Which stocks are comparable to Autolus Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Autolus Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Autolus Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.